• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Molecular mechanisms of duplicate resistance to FLT3 inhibitors in acute myeloid leukemia

Research Project

Project/Area Number 21K06585
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 47040:Pharmacology-related
Research InstitutionNihon University

Principal Investigator

KATAYAMA Kazuhiro  日本大学, 薬学部, 教授 (40406963)

Project Period (FY) 2021-04-01 – 2024-03-31
Project Status Completed (Fiscal Year 2023)
Budget Amount *help
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2023: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2022: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2021: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Keywords急性骨髄性白血病 / FLT3阻害薬 / 逐次治療 / 交差耐性 / Wnt/β-cateninシグナル / 二重変異 / 重複耐性 / Wntシグナル / バイパスシグナル / FLT3 / シグナル / 獲得変異
Outline of Research at the Start

FLT3阻害薬は2017年以降に承認された、新しい急性骨髄性白血病治療薬である。FLT3阻害薬単剤の使用では、阻害薬耐性が生じることが報告されている。今後は逐次治療が開始されると予想されるが、FLT3阻害薬に対する重複耐性の出現とFLT3遺伝子の獲得変異に関して把握されていない。本研究では、FLT3阻害薬による逐次治療で出現すると予想される重複耐性の分子機構を解明し、克服法を探索することを目的とする。本研究成果は、FLT3阻害薬による急性骨髄性白血病の逐次治療で生じた重複耐性に対する克服法の手がかりを与えるのみならず、FLT3遺伝子の獲得変異による耐性化の分子機構を理解する一助になる。

Outline of Final Research Achievements

The aim of this study was to analyze the mechanism of cross-resistance to FLT3 inhibitors for the treatment of acute myeloid leukemia and to search for ways to overcome it. Duplicated resistant cells established by sequential treatment with two different FLT3 inhibitors were cross-resistant to all FLT3 inhibitors. Proliferation of these cells was dependent on Wnt/β-catenin signaling, and the combination of both inhibitors acts synergistically. In addition, analysis of transfected cells revealed double mutations in FLT3 that are cross-resistant to FLT3 inhibitors. These double mutations were considered to alter the shape of the entrance to the ATP-binding site of FLT3, resulting in reduced inhibitory activity of the inhibitors. Thus, we found that after sequential use of FLT3 inhibitors, cross-resistance emerges due to the bypass pathway and double mutations in FLT3.

Academic Significance and Societal Importance of the Research Achievements

急性骨髄性白血病におけるFLT3阻害薬の交差耐性機構や、耐性克服に向けた戦略を発見できたことは、臨床現場でFLT3阻害薬に対する不応性や、治療後の再発を考察する一助になると期待される。急性骨髄性白血病では、分子標的薬の選択肢が少ないことや薬剤不応性・耐性などの問題があり、十分な生存率を望めないのが現状である。本研究成果に基づき治療戦略の見直しや治療薬の開発に繋がれば、急性骨髄性白血病治療の選択肢の幅が広がり、治療効果の向上に貢献できると推測される。治療効果の向上の恩恵を受けるのは急性骨髄性白血病患者であり、奏効・完治を達成できれば社会的な意義は非常に大きい。

Report

(4 results)
  • 2023 Annual Research Report   Final Research Report ( PDF )
  • 2022 Research-status Report
  • 2021 Research-status Report
  • Research Products

    (19 results)

All 2023 2022 2021

All Journal Article (8 results) (of which Int'l Joint Research: 1 results,  Peer Reviewed: 8 results,  Open Access: 4 results) Presentation (11 results) (of which Int'l Joint Research: 3 results)

  • [Journal Article] Kaposi's sarcoma-associated herpesvirus replication and transcription activator protein activates CD274/PD-L1 gene promoter.2023

    • Author(s)
      Miyazawa M, Yamamoto Y, Katayama K, Sugimoto Y, Noguchi K.
    • Journal Title

      CANCER SCIENCE

      Volume: ー Issue: 4 Pages: 1718-1728

    • DOI

      10.1111/cas.15673

    • Related Report
      2023 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Viral vector purification with thermoresponsive-anionic mixed polymer brush modified beads-packed column2022

    • Author(s)
      Nagase Kenichi、Kitazawa Sakiko、Kogure Toshihiko、Yamada Sota、Katayama Kazuhiro、Kanazawa Hideko
    • Journal Title

      Separation and Purification Technology

      Volume: 286 Pages: 120445-120445

    • DOI

      10.1016/j.seppur.2022.120445

    • Related Report
      2022 Research-status Report
    • Peer Reviewed
  • [Journal Article] Comparison of the inhibitory properties of the fruit component naringenin and its glycosides against OATP1A2 genetic variants.2022

    • Author(s)
      Naoya Araki, Tokio Morita, Takeshi Akiyoshi, Hiroki Kataoka, Kodai Yajima, Kazuhiro Katayama, Ayuko Imaoka, Hisakazu Ohtani.
    • Journal Title

      Drug Metab. Pharmacokinet.

      Volume: 46 Pages: 100464-100464

    • DOI

      10.1016/j.dmpk.2022.100464

    • Related Report
      2022 Research-status Report
    • Peer Reviewed
  • [Journal Article] Comparison of the transport kinetics of fexofenadine and its pH dependency among OATP1A2 genetic variants.2022

    • Author(s)
      Hongye Han, Takeshi Akiyoshi, Tokio Morita, Hiroki Kataoka, Kazuhiro Katayama, Kodai Yajima, Ayuko Imaoka, Hisakazu Ohtani.
    • Journal Title

      Drug Metab. Pharmacokinet.

      Volume: 47 Pages: 100470-100470

    • DOI

      10.1016/j.dmpk.2022.100470

    • Related Report
      2022 Research-status Report
    • Peer Reviewed
  • [Journal Article] Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML2022

    • Author(s)
      Yamatani K, Ai T, Saito K, Suzuki K, Hori A, Kinjo S, Ikeo K, Ruvolo V, Zhang W, Mak PY, Kaczkowski B, Harada H, Katayama K, Sugimoto Y, Myslinski J, Hato T, Miida T, Konopleva M, Hayashizaki Y, Carter BZ, Tabe Y, Andreeff M
    • Journal Title

      Translational Oncology

      Volume: 18 Pages: 101354-101354

    • DOI

      10.1016/j.tranon.2022.101354

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Inhibitory effects of cranberry juice and its ingredients on intestinal OATP1A2 and OATP2B1: Identification of avicularin as a novel inhibitor2022

    • Author(s)
      Morita T, Akiyoshi T, Tsuchitani T, Kataoka H, Araki N, Yajima K, Katayama K, Imaoka A, Ohtani H
    • Journal Title

      J Agric Food Chem

      Volume: 70 Issue: 10 Pages: 3310-3320

    • DOI

      10.1021/acs.jafc.2c00065

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] RSK Inhibition Induces Apoptosis by Downregulating Protein Synthesis in a Variety of Acute Myeloid Leukemia Cell Lines2021

    • Author(s)
      Katayama Kazuhiro、Nishihata Ayane
    • Journal Title

      Biological and Pharmaceutical Bulletin

      Volume: 44 Issue: 12 Pages: 1843-1850

    • DOI

      10.1248/bpb.b21-00531

    • NAID

      130008123418

    • ISSN
      0918-6158, 1347-5215
    • Year and Date
      2021-12-01
    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Inhibitory Potency and pH-dependence of OATP2B1 Inhibitors.2021

    • Author(s)
      Sato R, Akiyoshi T, Morita T, Katayama K, Yajima K, Kataoka H, Imaoka A, Ohtani H.
    • Journal Title

      Drug Metabol Pharmacokinet

      Volume: 41 Pages: 100416-100416

    • DOI

      10.1016/j.dmpk.2021.100416

    • Related Report
      2021 Research-status Report
    • Peer Reviewed
  • [Presentation] Novel dual resistance mechanism of acute myeloid leukemia cells to FLT3 inhibitors2023

    • Author(s)
      Kazuhiro Katayama
    • Organizer
      The 82nd Annual Meeting of the Japanese Cancer Association
    • Related Report
      2023 Annual Research Report
    • Int'l Joint Research
  • [Presentation] FLT3阻害薬重複耐性における新規耐性機序2023

    • Author(s)
      片山 和浩
    • Organizer
      第27回日本がん分子標的治療学会学術集会
    • Related Report
      2023 Annual Research Report
  • [Presentation] 急性骨髄性白血病細胞におけるFLT3阻害薬重複耐性の分子機構解析2023

    • Author(s)
      片山 和浩
    • Organizer
      日本薬学会第143年会
    • Related Report
      2022 Research-status Report
  • [Presentation] リネゾリドとリファンピシンの薬物間相互作用に関わる因子の探索2023

    • Author(s)
      井上 万莉、辻 泰弘、寺田 一樹、片山 和浩
    • Organizer
      日本薬学会第143年会
    • Related Report
      2022 Research-status Report
  • [Presentation] ロウバイ/ソシンロウバイ抽出物による急性骨髄性白血病細胞の増殖抑制2023

    • Author(s)
      近藤理佐子、菊地結、大越一輝、羽田紀康、片山和浩
    • Organizer
      日本薬学会第143年会
    • Related Report
      2022 Research-status Report
  • [Presentation] FLT3阻害薬に重複耐性を示す急性骨髄性白血病細胞の耐性機構解析2022

    • Author(s)
      片山和浩
    • Organizer
      第26回日本がん分子標的治療学会学術集会
    • Related Report
      2022 Research-status Report
  • [Presentation] Characterization of dual resistant AML cells to FLT3 inhibitors2022

    • Author(s)
      Kazuhiro Katayama
    • Organizer
      The 81st Annual Meeting of the Japanese Cancer Association
    • Related Report
      2022 Research-status Report
    • Int'l Joint Research
  • [Presentation] SYDE1 upregulates P-glycoprotein in human colorectal cancer SW620 cells2022

    • Author(s)
      Suguru Takeda; Shingo Kondo; Kazuhiro Katayama; Yu Kato; Yoshikazu Sugimoto
    • Organizer
      The 81st Annual Meeting of the Japanese Cancer Association
    • Related Report
      2022 Research-status Report
    • Int'l Joint Research
  • [Presentation] RSK阻害薬BI-D1870による急性骨髄性白血病細胞の増殖抑制2022

    • Author(s)
      片山和浩
    • Organizer
      日本薬学会第142年会
    • Related Report
      2021 Research-status Report
  • [Presentation] Molecular mechanisms underlying dual resistance to FLT3 inhibitors in AML cells2021

    • Author(s)
      Kazuhiro Katayama
    • Organizer
      The 80th Annual Meeting of the Japanese Cancer Association
    • Related Report
      2021 Research-status Report
  • [Presentation] RSK阻害薬BI-D1870はタンパク質合成を阻害し、急性骨髄性白血病細胞の増殖を抑制する2021

    • Author(s)
      片山和浩
    • Organizer
      第25回日本がん分子標的治療学会学術集会
    • Related Report
      2021 Research-status Report

URL: 

Published: 2021-04-28   Modified: 2025-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi